Scion Innovation Inc., a biotech company that merges living cells with engineered structures to test disease responses, among other services, has raised $350,000 of a $750,000 debt offering, according to a regulatory filing.

The company received a a Phase-I SBIR grant in June and a Biotechnology Center Research grant in 2014.

According to the company, it takes a systems engineering approach to achieve products for replicating human organ systems connected through microfluidics. SciKon’s microfluidic cell culture device improves the ability to predict human responses to drugs and toxicants using cell-based technologies in an accessible format.

Its products include device design protyping, human biology systems, animal biology, systems for thawing frozen cells, and more.

Scikon was founded in 2009.

The company is located ocated in Research Triangle Park, NC in close proximity to GlaxoSmithKline, National Institute of Environmental Health Science, Biogen, Bayer, Duke University and University of North Carolina and many others.

CEO Randall E. McClelland, Ph.D, says on the company web site:

“SciKon’s industrial and academic experiences are focused on bioengineered 2D and 3D environment-cell interactions. Our involvement includes human tissue procurement, primary cell development, bioreactor culture pharmaceutical trials, cryopreservation and cell thaw technology, and native “single organ” and “multi organ” in vitro co-culture systems. SciKon’s platforms are directed to improve medical and pharmaceutical biotools.”